We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

First Wave BioPharma Inc (FWBI) USD0.0001

Sell:$1.38 Buy:$1.45 Change: $0.15 (9.49%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$1.38
Buy:$1.45
Change: $0.15 (9.49%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Sell:$1.38
Buy:$1.45
Change: $0.15 (9.49%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

Contact details

Address:
777 Yamato Road, Suite 502
BOCA RATON
33431
United States
Telephone:
+1 (561) 5897020
Website:
https://www.firstwavebio.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FWBI
ISIN:
US33749P1012
Market cap:
$23.55 million
Shares in issue:
12.46 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • James Sapirstein
    Chairman of the Board, President, Chief Executive Officer
  • Daniel Schneiderman
    Chief Financial Officer
  • James Pennington
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.